Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Regen BioPharma Inc RGBP

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients. tCellVax is a cell-based immunotherapy that stimulates the patient’s immune system through gene silencing of NR2F6.


OTCPK:RGBP - Post by User

Post by Stockhunter101on Oct 09, 2023 8:23am
136 Views
Post# 35675715

#NewReport on @TheRegenBio $RGBP

#NewReport on @TheRegenBio $RGBPUser image

A new study report on Regen BioPharma, Inc. (OTCPK:RGBP) was

released by Goldman Small Cap study, a stock market research company

that specializes in the small cap and microcap sectors. Regen may be

prepared to launch a Phase I clinical trial in the broad field of autoimmune

therapeutics by using its extensive intellectual property (IP) and

unexpected outcomes from Phase I in vitro investigations.

Read more - 
https://bullish.link/RGBP_NEWS
<< Previous
Bullboard Posts
Next >>